Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

• Market Cap: AU$38.25M
• Dividend Yield: N/A
• Average Volume (3M): 306.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: N/A
• EPS Growth: -672.73%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 332,575,700
• 10 Day Avg. Volume: 291,172
• 30 Day Avg. Volume: 306,603
• PEG Ratio: 0.01
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$0.10 ▼(-3.00% Downside)

The score is primarily held back by weak financial performance (revenue collapse, ongoing losses, and cash burn) and a bearish technical setup (price below key moving averages with negative MACD). A debt-free balance sheet provides some stability, but negative earnings and no dividend data limit valuation support.

Positive Factors

Regulatory Approval

Receiving TGA approval for StemSmart™ marks a significant regulatory milestone, enhancing the company's credibility and paving the way for further clinical trials and potential market entry.

Strategic Partnerships

The partnership with Q-Gen Cell Therapies strengthens NSB's manufacturing capabilities, supporting scalability and readiness for commercialization, crucial for long-term growth in the biotech sector.

Innovative Product Development

The development of EmtinB™ for neuroprotection indicates NSB's commitment to innovation, potentially expanding its therapeutic portfolio and addressing unmet medical needs in neuroscience.

Negative Factors

Revenue Collapse

The collapse to zero revenue in 2025 highlights significant challenges in monetizing NSB's R&D efforts, impacting financial sustainability and necessitating reliance on external funding.

Cash Flow Weakness

Persistent negative cash flow underscores ongoing cash burn, typical of early-stage biotech firms, increasing dependency on external capital for operations and growth.

Profitability Challenges

Consistent operating losses reflect the high-risk nature of biotech R&D, with profitability challenges potentially limiting investment appeal and strategic flexibility.

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.

How the Company Makes Money

Neuroscientific Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company's key revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from product sales. NSB may also engage in research collaborations and partnerships with academic institutions and research organizations to advance its drug development programs. Additionally, the company might receive grants and funding from government and non-government organizations to support its research initiatives.

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Neuroscientific Biopharmaceuticals Ltd. faces significant financial challenges with inconsistent revenue and profitability. While the balance sheet remains debt-free, declining cash and assets present risks. Recent positive cash flow trends provide some optimism, but the company must address operational inefficiencies to achieve sustainable growth.

Income Statement

Neuroscientific Biopharmaceuticals Ltd. has experienced significant revenue volatility with a sharp decline to zero revenue in the most recent year. The net profit margin has improved from negative to positive, driven by a one-time gain rather than operational improvements. However, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a high equity ratio. However, the shrinking asset base and decreasing cash reserves signal potential liquidity issues. The company has managed liabilities effectively, but sustained negative income raises concerns about future financial stability.

Cash Flow

The recent improvement in free cash flow, from negative to positive, suggests improved cash management. However, the operating cash flow remains low relative to net income gains, indicating underlying operational inefficiencies. The positive trend in free cash flow is a promising sign for potential recovery.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	2.21M	4.95M	0.00	958.77K
Gross Profit	-92.78K	-92.78K	-91.34K	-57.85K	-64.92K	897.36K
EBITDA	-1.92M	-1.92M	-1.80M	-5.96M	-10.37M	-3.12M
Net Income	-1.85M	-1.85M	324.21K	-1.07M	-10.44M	-3.18M
Balance Sheet
Total Assets	16.96M	16.96M	5.44M	5.29M	7.74M	14.83M
Cash, Cash Equivalents and Short-Term Investments	7.27M	7.27M	4.95M	4.91M	7.22M	14.16M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	149.22K	149.22K	85.68K	597.36K	2.22M	223.41K
Stockholders Equity	16.81M	16.81M	5.35M	4.69M	5.52M	14.60M
Cash Flow
Free Cash Flow	-941.33K	-941.33K	42.43K	-2.30M	-6.95M	-2.63M
Operating Cash Flow	-941.33K	-941.33K	44.25K	-2.30M	-6.94M	-2.60M
Investing Cash Flow	-36.04K	-36.04K	-1.81K	0.00	-3.87K	-29.88K
Financing Cash Flow	3.29M	3.29M	0.00	0.00	0.00	13.51M

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.12, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.00 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYP	52 Neutral	AU$89.05M	-8.30	-138.54%	―	―	16.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPL	51 Neutral	AU$149.07M	-15.42	-41.51%	―	-40.74%	-21.21%
PTX	50 Neutral	AU$88.33M	-9.23	-49.72%	―	―	10.78%
NSB	44 Neutral	AU$38.25M	-13.10	-16.65%	―	―	-672.73%
ILA	43 Neutral	AU$121.07M	-19.03	-90.37%	―	―	26.38%
ADO	38 Underperform	AU$54.55M	-8.40	-159.86%	―	110.44%	35.90%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients

NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a successful clinical response, while the fourth patient showed a partial response with ongoing assessment. The strong outcomes in this hard-to-treat patient group are being used to shape the design of later-phase clinical trials expected to begin in the second half of 2026, underpin Phase 2 start-up activities including commercial manufacturing and regulatory planning, and support the company’s strategy to establish a foothold in the multibillion-dollar global Crohn’s disease market while expanding StemSmart™ as a broader platform therapy for chronic inflammatory indications.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection

NeuroScientific Biopharmaceuticals Ltd announced the results of its Annual General Meeting, where all resolutions were determined by a poll. The company is advancing its proprietary StemSmart technology to target fistulising Crohn’s disease, aiming for Phase 2 clinical trials to evaluate safety and efficacy. This initiative supports NSB’s strategy to obtain regulatory approval for its MSC therapy in Australia and internationally. Additionally, NSB’s EmtinB™ compound, which promotes neuroprotection and neuroregeneration, has shown promising preclinical results, demonstrating safety and specificity for its target receptor.

NeuroScientific Biopharmaceuticals to Host Investor Webinar on Strategic Advances

NeuroScientific Biopharmaceuticals Ltd. announced an upcoming investor webinar where CEO Nathan Smith will discuss the company’s recent performance and future milestones. The company is prioritizing its StemSmart technology for Crohn’s disease, aiming for Phase 2 trials, and is working on EmtinB™, a compound for neuroprotection, reflecting its commitment to innovative treatments in the biotechnology sector.

NeuroScientific Advances StemSmart™ Therapy for Crohn’s Disease

NeuroScientific Biopharmaceuticals has initiated treatment for the fourth patient under its Special Access Program using its StemSmart™ MSC therapy for fistulising Crohn’s disease, marking progress towards a Phase 2 clinical trial planned for 2026. This program provides critical real-world data to inform the trial design and offers a potential new therapeutic option for patients with severe, treatment-resistant Crohn’s disease, addressing a significant unmet medical need.

NeuroScientific Biopharmaceuticals Establishes Advisory Board to Drive Innovation

NeuroScientific Biopharmaceuticals Ltd has announced the formation of a Clinical & Scientific Advisory Board to guide its scientific innovation and product development. The board, led by Chief Medical Officer Dr. Catherine Cole, includes experts in nephrology, gastroenterology, and respiratory medicine. This strategic move aims to enhance the company’s clinical strategy and address unmet medical needs in immune-mediated inflammatory disorders.

NeuroScientific Biopharmaceuticals Advances StemSmart™ for Crohn’s Disease with Strategic Appointments and Partnerships

NeuroScientific Biopharmaceuticals Limited has announced significant progress in its clinical development efforts for StemSmart™, a treatment for Crohn’s disease. The company has received approval from the TGA for its initial patients in the Special Access Program, a crucial step towards a Phase 2 Clinical Trial. The appointment of Dr. Catherine Cole as Chief Medical Officer and Nathan Smith as CEO brings valuable expertise to the company, enhancing its capabilities in clinical development and manufacturing. Additionally, NSB has partnered with Q-Gen Cell Therapies to scale its manufacturing process, positioning the company for future clinical trials and commercialization.

Neuroscientific Biopharmaceuticals Expands Manufacturing and Proves Clinical Efficacy

Neuroscientific Biopharmaceuticals Ltd. has announced an expansion in manufacturing capacity through a technology transfer with Q-Gen, enhancing its supply chain for stem cell solutions. The company has demonstrated proven clinical efficacy with a 78% overall response rate in a refractory Crohn’s trial, positioning itself strongly in the market for auto-immune disorder treatments.